



July 07, 2011 12:00 PM Eastern Daylight Time

ABL DeepChek™ Using High-Throughput Sequencing Systems Aids in the Generation of Clinically Meaningful Genotyping Reports for Personalized Healthcare

LUXEMBOURG--(BUSINESS WIRE)--Advanced Biological Laboratories (ABL), a Luxembourg-based biotech company, and developers of the TherapyEdge™-ViroScore™ platform, are pleased to announce a poster presentation at the 20th International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies held in Los Cabos (Mexico). Researchers reported, in the context of the PRIUS study, the use of the first complete clinical genotyping solution using high-throughput sequencing with the GS Flex System from 454 Life Sciences, a Roche Company, and an innovative downstream analysis and reporting software package, DeepChek™-HIV, from ABL. This integrated solution processes large HIV sequencing information, analyzes and generates clinically meaningful genotyping reports towards personalized patient management.

ABL, Roche Diagnostics Spain and CIBERHED, a network of liver diseases specialists in Spain, have recently announced their collaboration on the development of a complete high-throughput sequencing-DeepChek™-HEP solution for viral hepatitis infections too.

The experience in HIV disease management and the future accomplishments planned in the field of viral hepatitis suggest that the TherapyEdge™ platform with its DeepChek™, offers to virology laboratories a simplified and efficient platform with a powerful database and analysis system combining high-throughput sequencing data with clinical and biological outcomes. These next generation drug resistance genotyping systems will be shortly more widely used for research and also for optimal routine analytical applications in various chronic disease areas. Automation will ensue and pricing become more affordable.

"With next-generation sequencing (NGS) tools and services integrated with a clinical, biological and molecular platform like TherapyEdge™, scientists will be able to achieve effective personalized medicine in most of the complex chronic diseases. We foresee that it shall make obsolete the Sanger based sequencing methods in the next 3 to 5 years " explained Dr. Chalom B. Sayada, CEO of ABL.

"New NGS markets will continue to emerge and expand. The next generation cancer and cardio-vascular diagnostic products already offer new assays and even newer more advanced ones are in the diagnostic pipeline. The TherapyEdge™-DeepChek™ platform will play a strategic role in helping medical staff and stakeholders in the healthcare sector to identify and use genetic biomarkers that are strategic and clinically relevant to enhance the understanding of new therapies and provide improved tools to our healthcare systems" said Dr. Sayada.

Contacts

Dr Chalom B. Sayada (CEO)

Email: info@ablsa.com

+352-2638-8921